{
    "clinical_study": {
        "@rank": "55177", 
        "acronym": "SGI-110", 
        "arm_group": [
            {
                "arm_group_label": "SGI-110 and Carboplatin", 
                "arm_group_type": "Experimental", 
                "description": "Part 1: Patients will be dosed with SGI-110 and carboplatin"
            }, 
            {
                "arm_group_label": "SGI-110 and carboplatin or Treatment of Choice", 
                "arm_group_type": "Experimental", 
                "description": "Part 2: Patients will be randomized to receive SGI-110 and carboplatin or Treatment of Choice.  Treatment of choice is at the discretion of the investigator and can be one of three standard of care treatments (topotecan, paclitaxel or pegylated liposomal doxorubicin)."
            }
        ], 
        "brief_summary": {
            "textblock": "A 2-part, Phase 1-2 controlled, open-label, randomized study in patients with\n      platinum-resistant recurrent ovarian cancer.  In Part 1, patients will receive SGI-110 and\n      carboplatin.  The optimum dose will be identified in Part 1 based on safety and efficacy.\n      In Part 2, patients will be randomized to receive the dose identified in Part 1 plus\n      carboplatin or one of three treatment of choice at the discretion of the investigator.  The\n      treatment of choice consists of topotecan, pegylated liposomal doxorubicin, or paclitaxel."
        }, 
        "brief_title": "SGI-110 in Combination With Carboplatin in Ovarian Cancer", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients who are women 18 years of age or older.\n\n          2. Patients who have histologically or cytologically confirmed recurrent high-grade\n             serous epithelial ovarian cancer (Grade 2 or 3), primary peritoneal carcinomatosis or\n             fallopian tube cancer.\n\n          3. Patients who have platinum-resistant disease (defined as having relapsed within 6\n             months of her last platinum-containing regimen). There is no limit on the number of\n             prior treatment regimens in Part 1. In Part 2, patients may have had no more than 3\n             prior cytotoxic treatment regimens, excluding adjuvant or maintenance therapy.\n\n          4. Patients must have had prior paclitaxel treatment.\n\n          5. Patients who have measurable disease according to RECIST v1.1 or detectable disease.\n\n          6. Patients with ECOG performance status of 0 or 1.\n\n          7. Patients with acceptable organ function.\n\n          8. Patients must be at least 3 weeks from last chemotherapy.\n\n        Exclusion Criteria:\n\n          1. Patients who have hypersensitivity to SGI-110 and/or carboplatin or other components\n             of these drug products.\n\n          2. Patients who have received prior therapy with any hypomethylating agents.\n\n          3. Patients who are refractory to platinum treatment i.e., progressed while on platinum\n             treatment.\n\n          4. Patients with abnormal left ventricular ejection fraction.\n\n          5. Patients with Grade 2 or greater neuropathy.\n\n          6. Patients with known brain metastases.\n\n          7. Patients with known history of HIV, HCV or HBV."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "116", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01696032", 
            "org_study_id": "SGI-110-02"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "SGI-110 and Carboplatin", 
                    "SGI-110 and carboplatin or Treatment of Choice"
                ], 
                "intervention_name": "SGI-110 and carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SGI-110 and carboplatin or Treatment of Choice", 
                "description": "Investigator may choose to treat with either topotecan, pegylated liposomal doxorubicin, or paclitaxel", 
                "intervention_name": "Treatment of Choice ( topotecan, pegylated liposomal doxorubicin, or paclitaxel)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Carboplatin", 
                "Paclitaxel", 
                "Topotecan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Ovarian Cancer", 
        "lastchanged_date": "May 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Norris Comprehensive Cancer Center- University of Southern California"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Cedars Sinai Medical Center - Samuel Oschin Comprehensive Cancer Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32610"
                    }, 
                    "name": "University of Florida Shands Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30912"
                    }, 
                    "name": "Georgia Health Sciences University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Melvin and Bren Simon Cancer Center- Indiana University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Covington", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70433"
                    }, 
                    "name": "Women's Cancer Care"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "Johns Hopkins Kimmel Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brightwaters", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11718"
                    }, 
                    "name": "Island Gynecologic Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke Cancer Institute- Duke University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "University of Cincinnati Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75201"
                    }, 
                    "name": "Mary Crowley Medical Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Falls Church", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22042"
                    }, 
                    "name": "Inova Fairfax Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T2N 4N2"
                    }, 
                    "name": "Tom Baker Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 5C2"
                    }, 
                    "name": "Juravinski Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Princess Margaret Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2L 4M1"
                    }, 
                    "name": "CHUM Gynecologie-Oncologie, Notre Dame Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United Kingdom", 
                        "zip": "BS2 8ED"
                    }, 
                    "name": "Bristol Heamatology and Oncology Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "zip": "LS9 7TF"
                    }, 
                    "name": "St. James Univesity Hospital - St. James Institute of Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "W12 0NN"
                    }, 
                    "name": "Imperial College Health Care NHS Trust-Garry Weston Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "EC1V 4AD"
                    }, 
                    "name": "Cambridge University Hospitals NHS Foundation and Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London CET", 
                        "country": "United Kingdom", 
                        "zip": "NW1 2PG"
                    }, 
                    "name": "Univesity College Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Middlesex", 
                        "country": "United Kingdom", 
                        "zip": "HA6 2RN"
                    }, 
                    "name": "Mount Vernon Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "zip": "SM2 5PT"
                    }, 
                    "name": "Royal Marsden Foundation Trust"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number of patients with adverse events\nIncidence of dose limiting toxicities", 
                "measure": "Part 1 (Safety Lead-In): Assess the safety and tolerability of SGI-110 and carboplatin by the incidence of dose limiting toxicities and other adverse events to determine the maximum tolerated dose for Part 2", 
                "safety_issue": "Yes", 
                "time_frame": "9 months"
            }, 
            {
                "description": "Change in CA-125 tumor biomarker every 4 weeks\nChange in tumor measurements by RECIST 1.1 every 8 weeks", 
                "measure": "Part 2 (Randomized, Controlled, Open Label): Assess and compare progression free survival (PFS) between SGI-110 and carboplatin and Treatment of Choice arms", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01696032"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical responses based both on measurable disease and detectable disease", 
                "measure": "Objective response rate (complete and partial responses)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Assessment of progression free survival as measured by weeks", 
                "measure": "Progression free survival at 6 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Assessment of clinical benefit rate as measured by weeks", 
                "measure": "Clinical benefit rate (complete response + partial response + stable disease for at least 3 months)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Percentage of patients with CA-125 reduction by \u2265 50%", 
                "measure": "CA-125 reduction", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Duration of response measured in weeks", 
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Overall survival measured in weeks", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Cmax, Cmin, AUC and other secondary PK parameters of SGI-110, decitabine and carboplatin in all patients during Cycle 1", 
                "measure": "Pharmacokinetics of combination treatment of SGI-110 and carboplatin", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Astex Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astex Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}